Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 20;9(3):e025687.
doi: 10.1136/bmjopen-2018-025687.

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

Y K Onno Teng  1 , Ian N Bruce  2 , Betty Diamond  3 , Richard A Furie  4 , Ronald F van Vollenhoven  5 , David Gordon  6 , James Groark  7 , Robert B Henderson  8 , Mary Oldham  8 , Paul P Tak  8
Affiliations

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

Y K Onno Teng et al. BMJ Open. .

Abstract

Introduction: Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and extrarenal lupus. These biologics, which operate through complementary mechanisms, might result in an enhanced depletion of circulating and tissue-resident autoreactive B lymphocytes when administered together. Thus, belimumab and rituximab combination may be a highly effective treatment of SLE. This study aims to evaluate and compare the efficacy, safety and tolerability of subcutaneous (SC) belimumab and a single cycle of rituximab in patients with SLE with belimumab alone.

Methods and analysis: BLISS-BELIEVE is a three-arm, randomised, double-blind, placebo-controlled, 104-week superiority study. Two hundred adults with SLE will be randomised 1:2:1 to arm A, belimumab SC 200 mg/week for 52 weeks plus placebo at weeks 4 and 6; arm B, belimumab SC 200 mg/week for 52 weeks plus rituximab 1000 mg at weeks 4 and 6; arm C, belimumab SC 200 mg/week plus standard of care for 104 weeks. The 52-week treatment period (arms A and B) is followed by a 52-week observational phase. The primary efficacy endpoint is the proportion of patients with disease control (SLE Disease Activity Index (SLEDAI)-2K≤2, without immunosuppressants and with a prednisone-equivalent dose of ≤5 mg/day) at week 52. Major secondary efficacy endpoints are the proportion of patients in clinical remission (defined as SLEDAI-2K=0, without immunosuppressants and corticosteroids) at week 64, and the proportion of patients with disease control at week 104. Safety endpoints include the incidence of adverse events (AEs), serious AEs and AEs of special interest.

Ethics and dissemination: Within 6 months of the study's primary manuscript publication, anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

Trial registration number: NCT03312907; Pre-results.

Keywords: clinical trials; rheumatology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: YKOT’s work is funded by the Netherlands Scientific Organisation and the Dutch Kidney Foundation (KJPB12.028 & 17OKG04). INB is a National Institute for Health Research (NIHR) Senior Investigator and is funded by Arthritis Research UK and the NIHR Manchester Biomedical Research Centre. INB has also received speaker’s bureau and advisory board grants from UCB, has participated in advisory boards and steering committees for AstraZeneca, is a member of Independent Data Safety Boards for Medimmune and Merck Serono, has received grants from Genzyme Sanofi and has participated in advisory boards for Eli Lilly. BD is an investigator on the CALIBRATE study, which is sponsored by National Institute of Allergy and Infectious Diseases. RAF has received grants and is a consultant for GSK and Genentech/Roche. RFvV has received grants and is a consultant for AbbVie, BMS, GSK, Pfizer and UCB, and is a consultant for Celgene, Biotest, Janssen, Lilly and Novartis. DG was an employee of GSK at the time of protocol development and holds shares in BMS. JG, RBH, MO (and her husband) and PPT are employees of GSK and hold shares in the company. RBH has a patent pending (patent number WO 2017050833 A1) related to this work.

Figures

Figure 1
Figure 1
Study design. IV, intravenous; PBO, placebo; RTX, rituximab; SC, subcutaneous; SoC, standard of care; W, week.
See this image and copyright information in PMC

References

    1. Dörner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010;125:464–75. 10.1016/j.pharmthera.2010.01.001 - DOI - PubMed
    1. D’Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. The Lancet 2007;369:587–96. 10.1016/S0140-6736(07)60279-7 - DOI - PubMed
    1. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009;5:400–4 https://www.nature.com/articles/nrrheum.2009.106#supplementary-information 10.1038/nrrheum.2009.106 - DOI - PubMed
    1. Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis 2017;76:547–53. 10.1136/annrheumdis-2016-209489 - DOI - PubMed
    1. van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958–67. 10.1136/annrheumdis-2013-205139 - DOI - PubMed

Publication types

MeSH terms

Associated data